Introduction {#Sec1}
============

Although most respiratory tract infections (RTIs) are due to viral infections, they cause the majority of antibiotic prescriptions in primary care \[[@CR1]\]. Most patients suffering from RTI do not benefit from an antibiotic treatment since severity and duration of the disease are not relevantly altered. On the contrary, many patients experience side effects such as diarrhoea and rash \[[@CR2]\]. Additionally, unnecessary antibiotic prescriptions contribute to increasing bacterial resistance to standard antibiotics \[[@CR3]\].

Various interventions have been evaluated to reduce antibiotic prescribing for RTI, e.g. public campaigns, distribution of printed educational material or group education meetings \[[@CR4]--[@CR6]\]. A recent systematic review found moderate short-term effects on antibiotic prescribing of interventions facilitating shared decision-making \[[@CR7]\]. Another global review summarised the effects of antimicrobial stewardship programs in ambulatory care including interventions for all infectious conditions and children. This review found low-strength evidence for interventions including provider and/or patient education, guidelines, delayed prescribing (DP) and computerised clinical decision support systems (CDSS) \[[@CR8]\]. It is expected that within the next years, antibiotic stewardship programs will need to be established worldwide \[[@CR9]\]. So far, there is still a discussion and uncertainty about which specific elements of interventions lead to high effectiveness and sustainability \[[@CR10]\]. Therefore, this review aims to update and summarise current evidence of various interventions in primary care on reducing antibiotic prescription rates (Abx prescription rates) due to acute RTIs in patients ≥ 13 years.

Methods {#Sec2}
=======

This is a systematic review reported according to the PRISMA Statement \[[@CR11]\]. This systematic review was not registered.

Search methods for identification of trials {#Sec3}
-------------------------------------------

The systematic literature search was carried out in MEDLINE/PubMed and the Cochrane Library using the following search terms:

((antibiotic\*) AND ("respiratory tract infection" OR "respiratory tract infections" OR "res-piratory infection") AND (communication OR training OR "point of care test" OR "rapid strep test" OR "delayed prescribing" OR intervention\* OR "electronic decision support" OR "clinical decision support system" OR "clinical decision support systems" OR "shared decision making") AND ("primary care" OR "primary health care" OR "medical care")) OR (("Anti-Bacterial Agents"\[Mesh\]) AND ("Respiratory Tract Infections"\[Mesh\]) AND ("Primary Health Care"\[Mesh\] OR "Physicians, Primary Care"\[Mesh\]))

Additionally, the bibliographies of the included trials were screened for relevant intervention trials. We could not search further databases like EMBASE due to limited access and lack of funding.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

The literature search included (cluster-) randomised controlled trials (RCTs) investigating the effect of interventions aiming to reduce antibiotic prescriptions for RTIs for patients ≥ 13 years in primary care settings. We excluded pilot trials and non-randomised trials. Eligible interventions were educational seminars, feedback on prescribing behaviour, patient education, communication skills training (CST) for physicians and diagnostic tools such as point-of-care tests (POCT) or (electronic) CDSS. We did not take public campaigns into account. These address a broad audience and use mass media to raise awareness for the problem of inadequate antibiotic prescribing and its influence on bacterial resistance. As our systematic review focuses on primary care, this type of intervention is not considered.

We investigated the primary outcome of Abx prescription rate as well as the number of antibiotic prescriptions for acute upper/lower RTIs (cough and sore throat). Any reported secondary outcome such as patient's reconsultation rate, days to recovery from RTI, prescribed class of antibiotic, rate of inappropriate antibiotic prescriptions (prescriptions not according to guidelines), Abx prescription rate for specific RTIs or usage of diagnostic devices was of interest to this systematic review.

We only included patients ≥ 13 years as we know that clinical decision-making in paediatric medicine differs from adults. Further, the communication in dyadic consultations between adults differs from "doctor-parent-child triads" and requests other communication styles \[[@CR12]\]. In consequence, we excluded children under 13 years. We included primary care physicians working in ambulatory care. Due to different health systems, we included physicians working in practices or primary care clinics.

We only considered publications written in English, German or French dated January 2005 till July 2016.

Trial selection {#Sec5}
---------------

Two reviewers (AK, SR or JFC) independently reviewed the titles, index terms and abstracts of the identified references and rated each paper as potentially relevant or not. Discrepancies were resolved by consensus.

Data extraction {#Sec6}
---------------

Relevant information for each trial included into the review was extracted by one reviewer and controlled independently by another one (AK, SR). Discrepancies were resolved by consensus. Three authors had to be contacted due to missing or unclear data about the age of included patients \[[@CR13]--[@CR15]\]. Gjelstad et al. offered odds ratios (OR) for antibiotic prescriptions for the age group ≥ 13 years, but no Abx prescription rate. It was possible to get unpublished Abx prescription rates for the subgroup of patients ≥ 13 years \[[@CR14]\]. Missing data---like *p* values or absolute numbers of antibiotic prescriptions---was indicated as "not specified" in our tabular summaries of included RCTs (see Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 1Antibiotic prescription rate of trials with baseline data and post-intervention measurementsStudyAbsolute number of prescribed Abx (in %/95% CI/*p* value) for IG and GC; adjusted OR; RRDifference in Abx prescription rates between corresponding study arms (in %)/difference in differences for Abx prescriptions between IG and CGOdds ratio for Abx prescriptions (95% CI, *p* value)Absolute reduction of Abx prescriptions in the corresponding study arm (in %)Bjerrum et al. 2006\
SpainT0:\
IG: n.s. (36%/29--44%/n.s.)\
CG: not performed\
T1:\
IG: n.s. (24%/20--29%/n.s.)\
CG: n.s. (32%/27--38%/n.s.)T0:\
n.s.\
T1:\
Δ (IG − CG) = − 12%\
Difference in differences:\
n.s.T0:\
n.s.\
T1:\
IG and CG: 0.67IG:\
Δ (T1 − T0) = − 12%\
CG:\
n.s.Altiner et al. 2007\
GermanyT0:\
IG: n.s. (36.4%/n.s./n.s.)\
CG: n.s. (54.7%/n.s./n.s.)\
T1:\
IG: n.s. (29.4%/n.s./n.s.)\
Adjusted OR for IG: 0.58 (95% CI 0.43--0.78, *p* \< 0.001)\
CG: n.s. (59.4%/n.s./n.s.)\
Adjusted OR for CG: 1.52 (95% CI 1.19--1.95, *p* = 0.001)\
T2:\
IG: n.s. (36.7%/n.s./n.s.)\
Adjusted OR for IG: 0.72 (95% CI 0.54--0.97, *p* = 0.028)\
CG: n.s. (64.8%/n.s./n.s.)\
Adjusted OR for CG: 1.31 (95% CI 1.01--1.71, *p* = 0.044)T0:\
Δ (IG − CG) = − 18.3%\
T1:\
Δ (IG − CG) = − 30%\
T2:\
Δ (IG − CG) = − 28.1%\
Difference in differences:\
IG for T2: − 9.8%T0:\
IG and CG: 0.47\
T1:\
IG and CG: 0.28\
T2:\
IG and CG: 0.31IG:\
Δ (T1 − T0) = − 7%\
Δ (T2 − T1) = − 7.3%\
Δ (T2 − T0) = + 0.3%\
CG:\
Δ (T1 − T0) = + 4.7%\
Δ (T2 − T1) = + 5.4%\
Δ (T2 − T0) = + 10.1%Gonzales et al. 2013\
USAT0:\
IG 1: n.s. (80%/n.s./n.s.)\
IG 2: n.s. (74%/n.s./n.s.)\
CG: n.s. (72.5%/n.s./n.s.)\
T1:\
IG 1: n.s. (68.3%/n.s./n.s.)\
IG 2: n.s. (60.7%/n.s./n.s.)\
CG: n.s. (74.3%/n.s./n.s.)T0: Δ (IG 2 − IG 1) = − 6%\
Δ (IG 1 − CG) = + 7.5%\
Δ (IG 2 − CG) = + 1.5%\
T1:\
Δ (IG 2 − IG 1) = − 7.6% (*p* = 0.67)\
Δ (IG 1 − CG) = − 6% (*p* = 0.003)\
Δ (IG 2 − CG) = − 13.6% (*p* = 0.01)\
Difference in differences:\
For IG 1: − 13.5%\
For IG 2: − 15.1%T0:\
IG 1 and IG 2: 1.4\
IG 1 and CG: 1.52\
IG 2 and CG: 1.08\
T1:\
IG 1 and IG 2: 1.39\
IG 1 and CG: 0.75\
IG 2 and CG: 0.53I 1:\
Δ (T1 − T0) = − 11.7%\
I 2:\
Δ (T1 − T0) = − 13.3%\
C:\
Δ (T1 − T0) = + 1.8%Gjelstad et al. 2013\*\
NorwayT0:\
IG: n.s. (34.3%/31.8--36.9/n.s.)\
CG: n.s. (35.2%/CI 32.8--37.7/n.s.)\
T1:\
IG: n.s. (32.8%/30.3--35.3/n.s.)\
CG: n.s. (36.9%/34.2--39.7/n.s.)T0:\
Δ (IG − CG) = − 0.9%\
T1:\
Δ (IG − CG) = − 4.1%\
Difference in differences:\
IG: + 0.2%T0:\
IG and CG: 0.96\
T1:\
IG and CG: 0.83IG:\
Δ (T1 − T0) = − 1.52%\
(95% CI − 2.85 to − 0.18, *p* = 0.027)\
CG:\
Δ (T1 − T0) = + 1.70\
(95% CI 0.69--2.72, *p* = 0.002)Andreeva et al. 2014\
RussiaSubgroup of 13 physicians:\
T0:\
IG: 28/47 (59%/n.s./n.s.)\
CG: 21/34 (62%/n.s./n.s.)\
T1:\
IG: 30/81 (37%/n.s./n.s.) CG: 44/62 (71%/n.s./n.s.)\
T1 for all 18 GPs:\
IG: n.s. (37.6%/n.s./n.s.)\
CG: n.s. (58.9%/n.s./n.s.)\
T2 for all 18 GPs:\
IG: n.s. (40.6%/n.s./n.s.)\
CG: n.s. (71.8%/n.s./n.s.)T0:\
Δ (IG − CG) = − 3%\
T1 for subgroup of 13 GPs who also participated in baseline study:\
Δ (IG − CG) = − 34%\
T1 for all 18 GPs:\
Δ (IG − CG) = − 21.3% (*p* = 0.006)\
T2 for all 18 GPs:\
Δ (IG − CG) = − 31.2% (*p* = 0.0001)\
Difference in differences:\
n.s.T0 only for 13 GPs:\
IG and CG: 0.91\
T1 for subgroup of 13 GPs who also participated in baseline study:\
IG and CG: 0.24\
T1 for all 18 GPs:\
IG and CG: 0.42\
T2 for all 18 GPs:\
IG and CG: 0.27IG (subgroup of 13 GPs):\
Δ (T1 − T0) = − 22%\
CG (subgroup of 13 GPs):\
Δ (T1 − T0) = + 9%\
IG (all GPs):\
Δ (T2 − T1) = + 4%\
CG (all GPs):\
Δ (T2 − T1) = + 12.9%Gulliford et al. 2014\
UKT0:\
IG: n.s. (53%/n.s./n.s.)\
CG: n.s. (52%/n.s./n.s.)\
T1:\
IG: n.s. (52%/n.s./n.s.)\
CG: n.s. (52%/n.s./n.s.)T0:\
Δ (IG − CG) = + 1%\
T1:\
Δ (IG − CG) = 0%\
Adjusted mean difference (adjusted for pre-intervention value, as well as mean age and proportion of women at each practice): − 1.85% (95% CI 0.10--3.59%; *p* = 0.038)\
Difference in differences:\
IG: − 1%T0:\
IG and CG: 1.04\
T1:\
IG and CG: 1.00IG:\
Δ (T1 − T0) = − 1%\
CG:\
Δ (T1 − T0) = 0%Little et al. 2013\
Belgium, Spain, Wales, Great Britain, Poland, NetherlandsT0: 3742/6771 (55.3%/n.s./n.s.)\
T1:\
Abx prescription rates regarding study arms:\
CG: 508/870 (58%/n.s./n.s.), OR = 1.00\
Internet-based training for CRP-POCT: 368/1062 (35%/n.s./n.s.)\
OR = 0.54 (95% CI 0.40--0.68; *p* \< 0.001)\
Internet-based CST: 476/1170 (41%/n.s./n.s.)\
OR = 0.69 (95% CI 0.54--0.85; *p* \< 0.001)\
Internet-based CST + CRP-POCT: 366/1162 (32%/n.s./n.s.)\
OR = 0.46 (95% CI 0.35--0.60; *p* \< 0.001)\
Abx prescription rates regarding factorial groups:\
Cumulative non-CRP-training group: 984/2040 (48%/n.s./n.s.)\
Cumulative CRP-training group: 734/2224 (33%/n.s./n.s.)\
Cumulative non-CST group: 876/1932 (45%/n.s./n.s.)\
Cumulative CST group: 842/2332 (36%/n.s./n.s.)T1:\
Δ (cumulative CRP group − cumulative non-CRP group): − 15%\
Δ (cumulative CST group − cumulative non-CST group): − 9%\
Difference in differences:\
n.s.T0: n.s.\
T1:\
Cumulative CRP-training group and cumulative non-CRP training group: 0.54 (95% CI 0.42--0.69, *p* \< 0.0001)\
Cumulative CRP-training group and cumulative communication training group: 0.88\
Cumulative communication training group and cumulative non-communication training group: 0.69 (95% CI 0.54--0.87, *p* \< 0.0001)CG:\
Δ (T1T0) = + 3%\
Internet-based training for CRP-POCT:\
Δ (T1 − T0) = − 20%\
Internet-based communication training:\
Δ (T1 − T0) = − 14%\
Internet-based communication training + CRP-POCT:\
Δ (T1 − T0) = − 23%\
Cumulative non-CRP-training group:\
Δ (T1 − T0) = − 7%\
Cumulative CRP-training group:\
Δ (T1 − T0) = − 22%\
Cumulative no-CST group:\
Δ (T1 − T0) = − 10%\
Cumulative CST group:\
Δ (T1 − T0) = − 19%Meeker et al. 2016\
USAT0 for each study group:\
IG 1: 1057/2132 (49.6%/47.5--51.7/n.s.)\
IG 2: 497/1491 (33.3%/30.9--37.7/n.s.)\
IG 3: 433/1236 (35.0%/32.4--37.7/n.s.)\
IG 1 + 2: 702/1977 (35.5%/33.4--37.6/n.s.)\
IG 1 + 3: 368/1511 (24.4%/22.2--26.5/n.s.)\
IG 2 + 3: 782/2362 (33.1%/31.2--35.0/n.s.)\
IG 1 + 2 + 3: 558/2178 (25.6%/23.8--37.5/n.s.)\
CG: 692/1866 (37.1%/34.9--39.3/n.s.)\
T1 for each study group:\
IG 1: 722/2388 (30.2%/28.4--32.1/n.s.)\
IG 2: 324/1979 (16.4%/14.7--18.0/n.s.)\
IG 3: 311/1620 (19.2%/17.3--21.1/n.s.)\
IG 1 + 2: 341/2131 (16.0%/14.5--17.6/n.s.)\
IG 1 + 3: 139/2014 (6.9%/5.8--8.0/n.s.)\
IG 2 + 3: 340/2240 (15.2%/13.7--16.7/n.s.)\
IG 1 + 2 + 3: 249/2492 (10.0%/8.8--11.2/n.s.)\
CG: 502/2095 (24.0%/22.1--25.8/n.s.)T0:\
Δ (IG 1 − CG): + 12.5%\
Δ (IG 2 − CG): − 3.8%\
Δ (IG 3 − CG): − 2.1%\
Δ (IG 1 − IG 2): + 16.3%\
Δ (IG 1 − IG 3): + 14.6%\
Δ (IG 2 − IG 3): − 1.7%\
T1:\
Δ (IG 1 − CG): + 6.2%\
Δ (IG 2 − CG): − 7.6%\
Δ (IG 3 − CG): − 4.8%\
Δ (IG 1 − IG 2): + 13.8%\
Δ (IG 1 − IG 3): + 11%\
Δ (IG 2 − IG 3): − 2.8%\
Difference in differences:\
IG 1: − 6.3%\
IG 2: − 3.8%\
IG 3: − 2.7%\
IG 1 + 2: − 6.4%\
IG 1 + 3: − 4.4%\
IG 2 + 3: − 4.8%\
IG 1 + 2 + 3: − 2.5%T0:\
IG 1 and CG: 1.67\
IG 2 and CG: 0.85\
IG 3 and CG: 0.91\
IG 1 and IG2: 1.97\
IG 1 and IG 3: 1.83\
IG 2 and IG 3: 0.93\
T1:\
IG 1 and CG: 1.37\
IG 2 and CG: 0.62\
IG 3 and CG: 0.75\
IG 1 and IG 2: 2.21\
IG 1 and IG 3: 1.82\
IG 2 and IG 3: 0.83IG 1:\
Δ (T1 − T0) = − 19.4%\
IG 2:\
Δ (T1 − T0) = − 16.9%\
IG 3:\
Δ (T1 − T0) = − 15.8%\
IG 1 + 2:\
Δ (T1 − T0) = − 19.5%\
IG 1 + 3:\
Δ (T1 − T0) = − 17.5%\
IG 2 + 3:\
Δ (T1 − T0) = − 17.9%\
IG 1 + 2 + 3:\
Δ (T1 − T0) = − 15.6%\
CG:\
Δ (T1 − T0) = − 13.1%\
Adjusted analysis (hierarchical regression model) for factorial study groups:\
CG:\
Δ (T1 − T0) = − 11.0%\
IG 1:\
Δ (T1 − T0) = − 16%\
IG 2:\
Δ (T1 − T0) = − 18.1%\
IG 3:\
Δ (T1 − T0) = − 16.3%*n.s.* not specified, *IG* intervention group, *CG* control group, *RR* relative risk, *OR* odds ratio, *POCT* point-of-care testing, *CRP* C-reactive protein, *CDSS* clinical decision support system, *95% CI* 95% confidence interval\*Unpublished data for patient sample ≥ 13 years, provided by Gjelstad et al.Table 2Abx prescription rates of trials with one post-intervention measurementStudyAbsolute number of prescribed Abx (in %/95% CI/*p* value) for IG and CG; adjusted OR; RRDifference in Abx prescription rates between corresponding study arms (in %)Odds ratio for Abx prescriptions (95% CI; *p* value)Absolute reduction of Abx prescriptions in the corresponding study arm (in %)Briel et al. 2006\
SwitzerlandT1:\
IG 1: 46/293 (15.7%/n.s./n.s.)\
Adjusted OR: 0.86 (95% CI 0.4--1.93)\
IG 2: 35/259 (13.5%/n.s./n.s.)\
CG: 61/285 (21.4%/n.s./n.s.)T1:\
Δ (IG 2 − IG 1) = − 2.2%\
Δ (IG 1 − CG) = − 5.7%\
Δ (IG 2 − CG) = − 7.9%T1:\
IG 1 and CG: 0.68\
IG 2 and CG: 0.57\
IG 1 and IG 2: 1.19n.s.Linder et al. 2009 \[[@CR25]\]\
USAT0: unpublished data\
T1:\
IG: 4601/11954 (39%/n.s./n.s.)\
CG: 4316/10007 (43%/n.s./n.s.)T1:\
Δ (IG − CG) = − 4%T1:\
IG and CG: 0.83 (95% CI 0.6--1.2; *p* = 0.30)n.s.Cals et al. 2009\*\
NetherlandsAbx prescription rates regarding study arms (only for T1):\
POCT group: 43/110 (39%/25.6--52.6/n.s.)\
CST group: 28/84 (33%/19.5--47.1/n.s.)\
POCT + CST-group: 27/117 (23%/11.6--34.6**/**n.s.)\
Usual care: 80/120 (67%/53.9--79.5/n.s.)\
Abx prescription rates regarding factorial groups (T1 ± T2):\
POCT group:\
T1: 70/227 (30.8%/21.8--39.8/n.s.)\
T2: 102/227 (44.9%/35.2--54.6/n.s.)\
CG for POCT = no POCT group:\
T1: 108/204 (52.9%/43.0--62.8/n.s.)\
T2: 119/204 (58.3%/48.5--68.1/n.s.)\
Comparison of the 2 groups:\
T1: *p* \< 0.02\
T2: *p* \< 0.01\
CST group:\
T1: 55/201 (27.4%/25.6--36.6/n.s.)\
T2: 76/201 (37.8%/28.1--47.5/n.s.)\
CG for CST = no CST group:\
T1: 123/230 (53.5%/43.8--63.2/n.s.)\
T2: 145/230 (63%/53.6--72.4/n.s.)\
Comparison of the 2 groups:\
T1: *p* \< 0.01\
T2: *p* \< 0.001T1:\
Δ (POCT group − CG) = − 28%\
Δ (CST group − CG) = − 34%\
Δ (POCT/CST − CG) = − 44%\
Δ (POCT − CST) = + 6%\
Δ (POCT − POCT/CST) = + 16%\
Δ (CST − POCT/CST) = + 10%\
Δ (CST − POCT) = − 6%\
Δ (POCT/CS − TPOCT) = − 16%\
Δ (POCT/CST − CST) = − 10%\
Only calculation for T2\*\
Δ (cumulative POCT group − cumulative non-POCT group):\
− 13.4%\
Δ (cumulative CST group − cumulative non-CST group): − 25.2%T1:\
Cumulative POCT group and cumulative non-POCT group: 0.39\
Cumulative POCT group and cumulative CST group: 1.18\
Cumulative CST group and cumulative non-CST group: 0.33\
T2:\
Cumulative POCT group and cumulative non-POCT group: 0.58\
Cumulative POCT group and cumulative CST group: 1.34\
Cumulative CST group and cumulative non-CST group: 0.36n.s.Cals et al. 2010\*\
NetherlandsT1:\
IG: 56/129 (43.4%/n.s./n.s.)\
CG: 73/129 (56.6%/n.s./n.s.)\
RR = 0.77 (95% CI 0.56--0.98)\
T2:\
IG: 68/129 (52.7%/n.s./n.s.)\
CG: 84/129 (65.1%/n.s./n.s.)\
RR = 0.81 (95% CI 0.62--0.99)Only calculation for T2\
T2:\
Δ (IG − CG) = − 12.4%T1:\
IG and CG: 0.59\
T2:\
IG and CG: 0.6n.s.Linder et al. 2010\
USAT0: baseline (unpublished data)\
T1:\
IG: 3912/8406 (47%/n.s./n.s.)\
CG: 4761/10082 (47%/n.s./n.s.)T1:\
Δ (IG − CG) = 0%T1:\
IG and CG: 0.97 (95% CI 0.7--1.4, *p* = 0.87)n.s.Worrall et al. 2010\
CanadaT1:\
IG: 33/75 (43.2%/n.s./n.s.)\
CG: 32/74 (44%/n.s./n.s.)\
*p* = 0.924T1:\
Δ (IG − CG) = − 0.8%T1:\
IG and CG: 0.97n.s.Llor et al. 2011\
SpainT1:\
IG: 123/281 (43.8%/n.s./*p* \< 0.001)\
CG: 168/262 (64.1%/n.s./n.s.)T1:\
Δ (IG − CG) = − 20.3%T1:\
IG and CG: 0.46n.s.McGinn et al. 2013\
USAT1:\
IG: 171/586 (29.2%/n.s./n.s.)\
CG: 153/398 (38.4%/n.s./n.s.)\
Comparison IG/CG:\
RR 0.73 (95% CI 0.58--0.92, *p* = 0.008)\
age-adjusted RR 0.74 (95% CI 0.60--0.92; *p* = 0.008)T1:\
Δ (IG − CG) = − 9.2%T1:\
IG and CG: 0.66n.s.Hui Min Lee et al. 2016\
SingaporeT1:\
IG: 94/457 (20.6%/n.s./n.s.)\
CG: 81/457 (17.7%/n.s./n.s.)T1:\
Δ (IG − CG) = + 2.9%T1:\
IG and CG: 1.20 (95% CI 0.84--1.72, *p* = 0.313)n.s.*CRP* C-reactive protein, *CDSS* clinical decision support system, *95% CI* 95% confidence interval, *CST* communication skills training, *CG* control group, *n.s.* not specified, *IG* intervention group, *RR* relative risk, *OR* odds ratio, *POCT* point-of-care testing\*Cals et al. 2009 and Cals et al. 2010: Antibiotic prescription data of the patient sample were captured during the index consultation (T1) and within 28 days after the index consultation. As T2 prescription rates include T1 prescription rates, this study is considered as a study with one post-intervention measurement

Summary of Abx prescription rates for acute upper/lower RTI {#Sec7}
-----------------------------------------------------------

If available, antibiotic use was presented as the absolute number of prescribed antibiotics. In addition, relative Abx prescription rates expressed as a percentage---with the corresponding 95% confidence intervals (= 95% CI) and *p* values---were indicated as well as the difference of Abx prescription rates between intervention group (IG) and control group (CG) (in percent, OR, relative risks (RR) (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). The Abx prescription rates before (T0) and after the intervention (T1 or T2) were shown for trials providing pre-post comparison. As RCTs were heterogeneous in study design and therefore in time points for T1 or T2, we decided to not exclude RCTs by defining a binding point of time for T1 or T2. Details of included RCTs can be seen in a tabular summary of study characteristics.

Assessment of risk of bias {#Sec8}
--------------------------

Two researchers (AK with SR, FB or JFC) independently assessed the risk of bias using the *Cochrane Collaboration's tool for assessing risk of bias in randomised trials* (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR16]\]. We discussed and resolved discrepancies by consensus*.*Fig. 1Assessment of risk of bias. Legend: \*plus data from published study protocol. ![](13012_2018_732_Figa_HTML.gif){#d29e1776} low risk of bias. ![](13012_2018_732_Figb_HTML.gif){#d29e1779} high risk of bias. ![](13012_2018_732_Figg_HTML.gif){#d29e1782} unclear risk of bias

Evaluation of intervention effect {#Sec9}
---------------------------------

Due to the heterogeneity of study designs, outcome measures and Abx prescription rates, we considered a pooled estimate of the effect size with Cohen's *d* to be inappropriate \[[@CR17]\].

There is no consensus on which change in Abx prescribing rates marks a meaningful intervention effect. The difference between current Abx prescription rate and optimal prescription rate reflects the range for reducing antibiotic prescriptions to a meaningful extent. But the generalisability for determining an optimal rate is limited by patient age and condition with different likelihoods for bacterial genesis (pneumonia vs. common cold) \[[@CR18]\]. One report from the year 2016 states that 44% of all ambulatory antibiotic prescriptions in the USA are due to RTIs. It is said that 50% of these prescriptions are inappropriate leading to an optimal prescribing rate of about 20% for all RTIs \[[@CR18]\]. Another publication suggests a prescribing rate of 10--15% for acute cough \[[@CR19]\].

As a compromise in this complex field and to simplify the overview of clinically relevant reductions in Abx prescriptions, we will consider an absolute difference of 10% between IG and CG for studies with post-intervention as minimal important change. For studies with baseline and follow-up, we regard a difference in differences of 10% as minimal important change. We acknowledge that this threshold is arbitrary, but a different threshold would not have changed our findings fundamentally.

Results {#Sec10}
=======

Study selection {#Sec11}
---------------

We searched databases on the 31st of July in 2016 and identified 690 publications. Reviewers independently screened for potentially relevant publications and categorised 215 publications as potentially relevant. After removal of duplicates (*n* = 84), the remaining 151 titles and abstracts were screened for eligibility and discussed by the reviewers. Disagreements between reviewers were resolved by consensus. Major reasons for exclusion were different trial populations, e.g. including children, trials carried out in non-primary care settings and non-randomised study designs. We excluded 84 out of 151 publications. A total of 67 potentially relevant articles were fully screened for inclusion and exclusion criteria (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Process of trial selection. MeSH - medical subject heading

Seventeen trials were finally included in this analysis.

Description of included trials {#Sec12}
------------------------------

Seventeen RCTs met the inclusion criteria and were included in this review (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Thirteen trials were cluster RCTs based on physician-, practice- or educational group levels as clusters \[[@CR13]--[@CR15], [@CR20]--[@CR29]\]. Four RCTs were randomised at patient level \[[@CR30]--[@CR33]\]. The majority of trials used a two-arm study design \[[@CR13]--[@CR15], [@CR20], [@CR24], [@CR25], [@CR27], [@CR28], [@CR30]--[@CR33]\]. The remaining trials employed a three-arm \[[@CR21], [@CR23]\] or factorial study design \[[@CR22], [@CR26], [@CR29]\].Table 3Characteristics of studies with baseline data and post-intervention measurementsStudy, country and study designInclusion criteria for patientsNumber of patients (I/C)\*; average age of patients (I/C)\*; number of physicians (I/C\*)Intervention and control group\*Data collection periodsNumber of adverse events (e.g. hospitalisations, deaths) or side effectsBjerrum et al. 2006\
Spain\
Two-armed cluster-randomised controlled intervention study\> 14 years\
Consultation due to upper/lower RTIT0: 1114/not performed; n.r.\
T1: 1674/2462; n.r.\
Physicians on T0: 52\
Physicians on T1: 17/35IG: training for physicians + feedback and reflection of baseline---Abx prescription rate + introduction to POCT (CRP and RADT)\
CG: care as usualAbx prescription rate right after initial consultation:\
T0: only for IG (Dec.--Feb. 02/03)\
T1: 1 year after I (Dec.--Feb. 04/05)n.r.Altiner et al. 2007\
Germany\
Two-armed cluster-randomised controlled intervention study\> 16 years\
First episode of acute cough (no cough for the previous 8 weeks)T0: 753/898; 42.2/42\
T1: 675/885; 44.9/43.9\
T2: 787/920; 41.7/41.8\
Physicians on T0: 104\
Physicians on T1: 42/44\
Physicians on T2: 28/33IG: communication training for physicians + handouts for patients and waiting room poster\
CG: care as usualAbx prescription rate right after initial consultation:\
T0: Nov.--Jan. 03/04\
T1: 6 weeks after I (Feb.--Apr. 2004)\
T2: 1 year after I (Jan.--Mar. 2005)n.r.Gonzales et al. 2013\
USA\
Three-armed cluster-randomised controlled intervention study13--64 years\
Consultation due to uncomplicated acute bronchitis (ICD-9-CM code 466.0; ICD-9-CM code 490)\
(No RTI consultation in the last 30 days)T0:\
Arm 1: 3639; n.r.\
Arm 2: 2974; n.r.\
Arm 3: 3195; n.r.\
T1:\
Arm 1: 1001; n.r.\
Arm 2: 1017; n.r.\
Arm 3: 950; n.r.\
11 "practice centres" for each study arm\
Arm 1: 68 physicians\
Arm 2: 41 physicians\
Arm 3: 46 physiciansIG 1:\
1) Training for physicians (via "clinical champion")\
2) Patient brochure\
3) Examination room poster with clinical algorithm for acute bronchitis\
IG 2:\
1) and 2)\
instead of 3) ➔ clinical algorithm integrated in practice software\
CG: care as usualAbx prescription rate right after initial consultation:\
T0: baseline (3 successive winter periods from Oct. to Mar. 2007--2009)\
T1: Oct. 2009--Mar. 2010Hospitalisations and emergency room visits occurred rarely in all study arms (no published data)Gjelstad et al. 2013\*\*\
Norway\
Two-armed cluster-randomised controlled intervention study\> 13 years\
Consultation due to acute RTINumber of RTI consultations on T0 for patients \> 13 years: 43880/46518\
Number of RTI-consultations on T1 for patients \> 13 years: 47522/47868\
Number of physicians on T0:\
39 education groups (202 physicians); n.r./41 education groups (232 physicians); n.r.\
Number of physicians on T1:\
39 education groups (183 physicians); 48.3/40 education groups (199 physicians); 49.7IG 1:\
1) Meeting: guidelines for RTI and strategy of delayed prescribing; installation of additional program for 2 of 4 practice software (reminders to document the number of days for delayed prescribing)\
2) Meeting: feedback on prescribing rates based on individual data\
3) 1-day seminar: reinforcement of intervention\
IG 2:\
Training regarding adequate pharmacotherapy on patients \> 70 years in 2 group meetings and 1-day peer visit, based on individual prescribing rates; antibiotic therapy was not content2 data collection periods for Abx prescription rate:\
T0: (Abx prescription rate during 1 year before I by retrospective data analysis with special software)\
I: Dec. 2005--May 2006\
T1: Abx prescription rate during 1 year (after I)n.r.Little et al. 2013\
Belgium, Spain, Wales, Great Britain, Poland, Netherlands\
Multinational cluster-randomised controlled intervention study, factorial study design\> 18 years\
First episode of acute cough (max. of 28 days)\
First episode of upper/lower RTIT0: 6771; 49.6\
T1: 4264\
Arm 1 **=** CG: 870\
Arm 2 **=** IG 1: 1062\
Arm 3 **=** IG 2: 1170\
Arm 4 **=** IG 3: 1162\
Factorial groups:\
POCT-CRP-group (arms 2 + 4): 2224; 51.0\
CG for CRP-POCT = no CRP-POCT group (arms 1 + 3): 2040; 50.9\
CST-group (arms 3 + 4): 2332; 51.1\
CG for CST = no CST group (arms 1 + 2): 1932; 50.8\
Physicians on T0: 259 practices\
Physicians on T1: 228 practices; 372 physiciansCG:\
care as usual\
IG 1:\
Internet-based training for CRP-POCT\
IG 2:\
Internet-based communication training\
IG 3:\
Internet-based training for communication training + CRP-POCTAbx prescription rate right after initial consultation:\
T0: Oct.--Dec. 2010\
T1: Feb.--May 2011Deaths: none\
Hospitalisations:\
CG: 2\
IG 1: 10\
IG 2: 6\
IG 3: 12\
Difference in hospitalisation rate between cumulative CRP group and cumulative non-CRP group: 22/8 (OR\* = 2.91, 95% CI 0.96--8.85, *p* = 0.06)\
Cluster-adjusted: OR\* = 2·61, 95% CI 1.07--6.35, *p* = 0.034Andreeva et al. 2014\
Russia\
Two-armed cluster-randomised controlled intervention studyPatients ≥ 18 years with first episode of acute cough/lower RTI (including acute bronchitis, pneumonia and infectious exacerbations of COPD or asthma)T0 for subgroup of 13 GPs: 47/34; n.r.\
T1 for subgroup of 13 GPs: 81/62; n.r.\
T1: 101/78; 50.8/50.8\
Physicians: a total of 18 GPs participated, but only 13 GPs participated in baseline and intervention periodIG:\
1) Registration of patient's symptoms, clinical examination and therapy in electronic case report form\
2) 2 training sessions concerning the CRP test, guidelines about the interpretation of CRP results, discussion about paper cases of patients with different RTIs and different CRP values\
CG: 1)Abx prescription rate during I period (12 weeks---from 30 January to 30 April 2010)\
T0: only for 13 GPs 2 months before data collection\
T1: Abx prescription rate right after initial consultation\
T2: Abx prescription rate 2 weeks after initial consultationn.r.Gulliford et al. 2014\
UK\
Two-armed cluster-randomised controlled intervention studyPatients aged 18--59 years consulting for RTIT0: 292,398/264,137; n.r.\
T1: 294,929/263,895; n.r.\
50 family practices were allocated to IG, and 50 practices were allocated to CGIG: decision support tool including a summary of antibiotic prescribing recommendations and research evidence concerning no antibiotic or delayed antibiotic prescribing strategies + a single-sided patient information sheet, information on the definite indications for antibiotic prescription\
CG: care as usualAbx prescription rate during two 12-month data collection periods:\
T0: 12-month period before I\
T1: 12-month period after In.r.Meeker et al. 2016\
USA\
Cluster-randomised controlled intervention study, 2 × 2 × 2 factorial designPatients ≥ 18 years with no visit for acute RTI within the prior 30 daysNo. of patients: 14,753/16,959\
No. of patients T0/T1 for each study group:\
IG 1: 2132/2388\
IG 2: 1491/1979\
IG 3: 1236/1620\
IG 1 + 2: 1977/2131\
IG 1 + 3: 1511/2014\
IG 2 + 3: 2362/2240\
IG 1 + 2 + 3: 2178/2492\
CG: 1866/2095\
No. of practices/physicians for T0 and T1: 47/248\
No. of practices/physicians/mean age of patients for each study group:\
IG 1: 6/42/48\
IG 2: 7/35/53\
IG 3: 4/20/47\
IG 1 + 2: 6/34/50\
IG 1 + 3: 6/35/48\
IG 2 + 3: 6/27/49\
IG 1 + 2 + 3: 6/28/43\
CG: 6/27/497 IGs:\
I1: "Suggested alternatives"---EHR-based intervention (resembling CDSS) triggered by a RTI. User gets a list of alternative treatment (e.g. over-the-counter medicine)\
I2: "Accountable justification"---EHR-based I triggered by antibiotic prescriptions. User must explicitly justify the treatment decision.\
I3: "Peer comparison"---monthly e-mail with individual number and proportion of adequate and inadequate antibiotic prescriptions for acute RTI compared with other physicians\
I4: I1 + I2\
I5: I1 + I3\
I6: I2 + I3\
I7: I1 + I2 + I3\
CG: care as usualAbx prescription rate for inadequate antibiotic prescriptions for acute RTI\
T0: 18-month baseline for each practice\
T1: 18-month period (beginning Nov. 2011 to Oct. 2012, ending for the last practice in Apr. 2014)Return visit rate within 30 days after initial consultation in which no antibiotics were prescribed:\
Among CG practices: 0.43% (95% CI 0.25--0.70)\
Among I2 and I3 practices: 1.41% (95% CI 1.06--1.85, *p* \< 0.001)\
Among return visits, a random sample of 33 cases across all study groups was monitored for complications/hospitalizations:\
11 cases of pneumonia, 1 otitis media, 1 pneumonia + otitis media\
1 hospitalisation for pneumonia\**Abx prescription rate* antibiotic prescription rate, *CRP* C-reactive protein, *CDSS* clinical decision support systems, *CG* control group, *EHR* electronic health record, *IG* intervention group, *n*.*r*. not reported, *POCT* point-of-care-testing, *RADT* rapid antigen detection test, *RTI* respiratory tract infection\*\*Unpublished data for patient sample ≥ 13 years, provided by Gjelstad et al.Table 4Characteristics of trials with one post-intervention measurementStudy, country and study designInclusion criteria for patientsNumber of patients (I/C)\*; average age of patients (I/C)\*; number of physicians (I/C\*)Intervention and control group\*Data collection periodsNumber of adverse events (e.g. hospitalisations, deaths) or side effectsBriel et al. 2006\
Switzerland\
Three-armed cluster-randomised controlled intervention study\> 18 years\
First episode of acute RTI (symptoms for max. of 28 days)T1:\
"Unlimited" IG: 293; 43.6\
"Full" IG: 259; 41.4\
CG: 285; 40.5\
15 Physicians in each study group\
in total: 45 physicians in 45 practices"Limited" IG: guidelines on RTI\
"full" IG: additional 6-h seminar on patient-centred communication + 2-h telephone feedback\
CG: (care as usual)Abx prescription rate during 2 weeks after initial consultation, registered by study pharmacies\
T1: January--May 2004Number of deaths and hospitalisations:\
"Limited" IG: 1 death\
"Full" IG: 3 hospitalisations\
CG: noneCals et al. 2009\*\*\
Netherlands\
Cluster-randomised controlled intervention study, factorial design\> 18 years\
Acute cough due to lower RTI (max. of 4 weeks)T1 and T2:\
Arm 1: 110\
Arm 2: 84\
Arm 3: 117\
Arm 4: 120\
Factorial groups:\
POCT-group (arm 1 + arm 3): 227; 49.4\
CG for POCT = no POCT group (arm 2 + arm 4): 204; 50.3\
CST group (arms 2 + 3): 201; 51.4\
CG for CST = no CST group (arms 1 + 4): 230; 48.5; 10 physicians (5 practices) in each study arm on T1 and T2IG 1: POCT (CRP)\
IG 2: CST\
IG 3: POCT+CST\
CG: care as usualData collection in two winter periods 2005/2006 and 2006/2007:\
T1: after initial consultation\
T2: 28 days after initial consultationNo hospitalisations and deaths during the studyLinder et al. 2009\
USA\
Two-armed cluster-randomised controlled intervention studyConsultation due to upper/lower acute RTINumber of consultations due to RTI:\
T1: 11954/10007; 48/49\
Physicians on T1: 262/181 (in 27 "practice centres")IG: "ARI Smart Form" = CDSS\
Collection of patient data, documentation of diagnosis and therapy, presentation of therapy options with integrated CDSS\
Print-out option for patient handouts and specialised literature\
CG: care as usualAbx prescription rate right after initial consultation:\
T0: baseline\
T1: Abx prescription rate during intervention from November 2005 to May 2006n.r.Cals et al. 2010\*\*\
Netherlands\
Two-armed randomised controlled intervention study\> 18 years\
First episode of lower RTI or rhinosinusitis (max. for 4 weeks)T1 and T2:\
129/129; 43.0/45.5\
33 physicians (in 11 practices) on T1 and T2IG: POCT for CRP measurement, CRP-dependent prescribing strategies: immediate or delayed prescribing or no prescribing\
CG: care as usualTwo data collection periods from November 2007 to April 2008:\
T1: after initial consultation\
T2: 28 days after initial consultationNo hospitalisations and deaths during the studyLinder et al. 2010\
USA\
Two-armed cluster-randomised controlled intervention studyConsultation due to upper/lower acute RTINumber of consultations due to RTI:\
T1: 8406/10082; 49/49\
Physicians on T1: 258/315 in 27 "practice centres"IG: "ARI Quality Dashboard" = CDSS\
Collection of patient data, documentation of diagnosis and therapy, presentation of therapy options with integrated CDSS\
Comparison of indiv. Abx prescription rate with national RTI-prescribing data\
Management of billing data\
CG: care as usualAbx prescription rate right after initial consultation:\
T0: baseline\
T1: Abx prescription rate during intervention from November 2006 to August 2007n.r.Worrall et l. 2010\
Canada\
Two-armed randomised controlled intervention study\> 18 years\
patients with acute upper RTIT1: 75/74; n.r.\
Physicians on T1: 6Arm 1: delayed prescribing with "normal" prescription\
Arm 2: delayed prescribing with post-dated prescription (48 h after initial consultation)Abx prescription rate during 19 days after initial consultation:\
T1: n.r.n.r.Llor et al. 2011\
Spain\
Two-armed randomised controlled intervention study14--60 years\
patients with acute pharyngitis (≥ 1 censor criterion)T1: 281/262; 31.8/31.5\
Physicians on T1: 33/28\
10 "primary care centres" in IG and CGIG: RADT\* (Strep A-Test)\
CG: care as usualAbx prescription rate right after initial consultation:\
T1: January--May 2008Side effects of AB therapy (gastrointestinal side effects, rash):\
I: 32\
C: 8McGinn et al. 2013\
USA\
Two-armed cluster-randomised controlled intervention studyPatients \> 18 years were included, if electronic health record detected keywords (=diagnoses, symptoms associated with pharyngitis or pneumonia)T1: 586/398; 43/49\
In total: 168 assistant physicians, specialists and specialised nurses in 2 primary care practicesIG:\
1) 1-h training on Walsh score for streptococcal pharyngitis and Heckerling score for pneumonia\
2) Video presentation of CDSS\* and integration in practice software\
3) Entry of keywords in practice software (on pharyngitis and pneumonia); pop-up function of CDSS\* with following risk score calculation and corresponding recommendations\
CG:\
(Journal article about Walsh score for streptococcal pharyngitis and Heckerling score for pneumonia)T1: Abx prescription rate right after initial consultation (additionally prescribed Abx 2 weeks after initial consultation) in November 1, 2010--October 31, 2011Difference in emergency room visits between IG and CG: *p* \> 0.99\
Difference in follow-up treatment rate between IG and CG: *p* = 0.10Hui Min Lee et al. 2016\
SingaporeTwo-arm parallel group randomised controlled trialPatients ≥ 21 years presenting with at least one of four symptoms (runny nose, blocked nose, cough or sore throat) for 7 days or lessT1: 457/457; 36/35\
35 participating GPs from 24 clinicsIG: patients were educated on causes of upper respiratory tract infections\
CG: patients were educated on influenza vaccinationsAbx prescription rate after the initial consultation:\
T1: 8 working days in February 2015n. r.\**Abx prescription rate* antibiotic prescription rate, *CRP* C-reactive protein, *CDSS* clinical decision support systems, *CST* communication skills training, *CG* control group, *EHR* electronic health record, *IG* intervention group, *n*.*r*. not reported, *POCT* point-of-care-testing, *RADT* rapid antigen detection test, *RTI* respiratory tract infection\*\*Cals et al. 2009 and Cals et al. 2010: Antibiotic prescription data of the patient sample were captured during the index consultation (T1) and within 28 days after the index consultation. As T2 prescription rates include T1 prescription rates, this study is considered as a study with one post-intervention measurement

All cluster-randomised trials performed cluster-adjusted data analyses. The number of participating physicians ranged from 6 to 573. Most trials were conducted in Europe \[[@CR13], [@CR14], [@CR20]--[@CR22], [@CR27], [@CR28], [@CR31]\], six trials in North America \[[@CR15], [@CR23]--[@CR25], [@CR30], [@CR32]\] and one in Asia \[[@CR33]\]. One trial was a multinational project carried out in six European countries (Belgium, Spain, Wales, England, Poland and the Netherlands) \[[@CR26]\]. Published baseline data was available for seven trials \[[@CR14], [@CR20], [@CR23], [@CR26]--[@CR29]\]. Eleven trials assessed the Abx prescription rate right after patients' initial consultation \[[@CR13], [@CR20], [@CR22], [@CR23], [@CR26]--[@CR31], [@CR33]\].

Primary endpoints {#Sec13}
-----------------

Data on Abx prescription rates was collected directly by physicians \[[@CR20], [@CR21], [@CR26], [@CR27], [@CR31]\], by pharmacists using faxed or mailed prescriptions \[[@CR21], [@CR32]\], by field researchers \[[@CR33]\] or by electronic medical records \[[@CR13], [@CR15], [@CR22]--[@CR25], [@CR28], [@CR29]\]. Four trials used special documentation software \[[@CR14], [@CR23]--[@CR25]\].

The time period for registration of Abx prescriptions ranged from right after the initial consultation up to 28 days after initial consultation.

Six trials assessed effectiveness of the intervention after a longer period of time, within 1 year \[[@CR15], [@CR29]\] or within 18 months after the intervention \[[@CR30]\], after 1 year \[[@CR13], [@CR20]\] or after 3.5 years (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}) \[[@CR34]\].

Description of participating physicians {#Sec14}
---------------------------------------

Ten trials recruited primary care physicians in private practices \[[@CR13], [@CR14], [@CR20]--[@CR22], [@CR26]--[@CR29], [@CR32]\], and seven trials recruited physicians from primary care clinics \[[@CR15], [@CR23]--[@CR25], [@CR30], [@CR31], [@CR33]\].

Description of patient population {#Sec15}
---------------------------------

Patients ≥ 13 years with acute upper and lower RTIs were included. The average age of patients was similar across trials and ranged from 40 to 53 years. The number of registered consultations varied from 149 to 1,115,359 \[[@CR28], [@CR32]\].

Description of interventions {#Sec16}
----------------------------

### Multifaceted interventions {#Sec17}

Twelve RCTs used multifaceted interventions \[[@CR13], [@CR14], [@CR20]--[@CR26], [@CR28]--[@CR30]\]. Multifaceted interventions contain two or more components and address the different aspects of inadequate antibiotic prescribing. Due to the multifaceted interventions of the included trials, some of them are discussed repeatedly in the following subsections. For example, the factorial study design of Cals et al. allows reporting of the effect of the CST or POCT alone or combined \[[@CR22]\].

### Intervention elements addressing physicians {#Sec18}

Twelve trials used interventions that addressed physicians \[[@CR13], [@CR14], [@CR20]--[@CR24], [@CR26], [@CR28]--[@CR30], [@CR32]\]. Four different types of interventions were evaluated:A "classic" knowledge transfer approach using interactive seminars \[[@CR13], [@CR14], [@CR21]\] and distribution of printed teaching and information materials \[[@CR21], [@CR23]\] as well as feedback on individual Abx prescription rates \[[@CR13], [@CR14], [@CR21], [@CR22], [@CR24], [@CR29]\]. Themes discussed included diagnosis-making and therapy of RTIs in accordance with guidelines as well as the challenge of increasing bacterial resistance.A CST dealing with perceived pressure to prescribe where physicians learnt how to communicate with patients about their expectations on antibiotic prescribing and how to respond to patients' concerns. In three trials, physicians were trained in seminars \[[@CR20]--[@CR22]\]. One trial provided an Internet-based CST \[[@CR26]\].Physicians were introduced to the concept of DP. This implies advising patients with low probability of bacterial RTI to use a prescription for antibiotics only in case symptoms do not resolve or get worse up to a pre-defined point in time. Cals et al. combined this strategy with C-reactive protein (CRP) POCT \[[@CR30]\]. POCT are simple diagnostic tests and allow measuring CRP directly in the practice. CRP is an acute-phase protein with increasing plasma concentration during inflammatory processes. The measurement of CRP with a POCT has been proved accurate and can increase diagnostic certainty if combined with clinical examination---especially for identifying patients at high risk of pneumonia \[[@CR35], [@CR36]\]. Gjelstad et al. implemented additional software applications that asked physicians to specify whether the concept of DP was used and to document the number of days agreed to postpone antibiotic use \[[@CR14]\]. Worrall et al. compared two DP procedures---one of them employing a ready-to-use prescription and the other applying a post-dated prescription usable only up to 48 h after initial consultation \[[@CR32]\]. Gulliford implemented information about DP within a CDSS \[[@CR28]\].Electronic health records (EHR) asked physicians to justify their treatment decision if an antibiotic was ordered and provided alternative treatment interventions \[[@CR29]\].

### Intervention elements addressing patients {#Sec19}

Five trials implemented interventions addressing patients \[[@CR20], [@CR23], [@CR25], [@CR28], [@CR33]\]. Four trials used patient brochures with information about RTIs as adjunct \[[@CR20], [@CR23], [@CR25], [@CR28]\]. One trial used an additional waiting room poster addressing increasing bacterial resistance and prescribing pressure as one of the main reasons for inadequate prescribing \[[@CR20]\]. Linder et al. and Gulliford et al. implemented documentation software with the possibility to print patient information leaflets \[[@CR25], [@CR28]\]. In the RCT of Linder et al., it remained unclear how many physicians used this possibility \[[@CR25]\]. In the trial of Gulliford et al., the number of printed leaflets was low among the physicians with the highest utilisation of the CDSS (25 leaflets per 1000 consultations for RTI) \[[@CR28]\]. In the trial of Hui Min Lee et al., patients in the IG were educated on the aetiology of upper RTIs by trained field researchers prior to the consultation \[[@CR33]\].

### Intervention elements addressing improved diagnosis-making {#Sec20}

Twelve trials implemented interventions addressing diagnosis-making \[[@CR13], [@CR15], [@CR22]--[@CR31]\]. In one trial, the POCT was combined with a CST \[[@CR22]\]. Another trial combined POCT with the strategy of DP \[[@CR30]\]. Little et al. provided CRP-POCT training via the Internet \[[@CR26]\]. Andreeva et al. used the CRP-POCT as a single intervention \[[@CR27]\]. Bjerrum et al. employed a rapid antigen detection test for identifying group A streptococcal infections (RADT) in combination with feedback on personal prescribing rates \[[@CR13]\]. Llor et al. used the RADT by itself \[[@CR31]\]. The RADT is a fast pathogen identification test and can assist a physician in differentiating between a bacterial pharyngitis caused by group A streptococci or a viral infection. In combination with clinical scores such as the McIsaac score, it can raise diagnostic certainty and help to avoid unnecessary antibiotic prescriptions \[[@CR37]\].

Six trials made use of CDSS \[[@CR15], [@CR23]--[@CR25], [@CR28], [@CR29]\]. Linder et al. \[[@CR24], [@CR25]\] and McGinn et al. \[[@CR15]\] provided assistance for estimating the likelihood of a bacterial RTI \[[@CR24], [@CR25]\] or a pneumonia/streptococcal pharyngitis \[[@CR15]\]. Gulliford et al. provided evidence from research for antibiotic prescribing when a RTI was coded in an electronic medical record \[[@CR28]\]. Andreeva et al. compared two different methods of diagnostic assistance: a computer-based system and a poster with a clinical algorithm \[[@CR23]\]. Meeker et al. asked their participating physicians to justify their entered diagnosis and treatment \[[@CR29]\].

Effects of the intervention on Abx prescription rate (see Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} and Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}) {#Sec21}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Twelve trials reported statistically significant lowered Abx prescription rates in the IGs compared to CGs \[[@CR13]--[@CR15], [@CR20], [@CR22], [@CR23], [@CR26]--[@CR31]\]. In five RCTs. the Abx prescription rates could not be reduced significantly (see Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}) \[[@CR21], [@CR24], [@CR25], [@CR32], [@CR33]\]. Using our definition for a clinically relevant reduction of prescription as criterion for efficacy, only six trials had a meaningful effect on Abx prescription rates \[[@CR22], [@CR23], [@CR26], [@CR27], [@CR30], [@CR31]\]. The effect of the interventions cannot be compared directly due to heterogeneous study designs.Fig. 3Abx prescription rates of trials with baseline and post-intervention measurements. Rhombus = intervention group = ![](13012_2018_732_Figc_HTML.gif){#d29e3484}. Circle = control group = ![](13012_2018_732_Figd_HTML.gif){#d29e3487}. White = T0 = pre-intervention measurement/baseline. Grey = T1 = post-intervention measurement. Black = T2 = optional post-intervention measurement. 1 Results for subgroup of 13 physicians. 2 Evaluated by study team. 3 According to our definition: For studies with baseline and post-intervention measurements, a difference in differences of 10 percentage points within study arms is regarded as minimal important changeFig. 4Abx prescription rates of trials with post-intervention measurements. Rhombus = intervention group = ![](13012_2018_732_Fige_HTML.gif){#d29e3499}. Circle = control group = ![](13012_2018_732_Figf_HTML.gif){#d29e3502}. Grey = T1 = post-intervention measurement. 1 Cals et al. 2009 and Cals et al. 2010: Antibiotic prescription data of the patient sample was captured during the index consultation (T1) and within 28 days after the index consultation (T2). Abx prescription rates for study arms are only available for T1. 2 Evaluated by study team. 3 According to our definition: For studies with post-intervention measurements, a difference of 10 percentage points between CG and IG is regarded as minimal important difference

### Intervention effect of trials with baseline and post-intervention measurements {#Sec22}

The Abx prescription rates of studies with baseline and post-intervention measurements are provided in Fig. [3](#Fig3){ref-type="fig"}.

In the trial of Bjerrum et al., the CG has in contrast to the IG no pre-intervention measurement \[[@CR13]\]. All but one had an observation period ranging from measurement direct after the consultation up to 1 year \[[@CR27]\]. The baseline prescription rates ranged from 24.4% \[[@CR29]\] to 80% \[[@CR23]\]. All studies found statistically significant results within and/or in-between study arms. The trial of Altiner et al. showed a large difference in baseline prescription rates, indicating the possibility of selection bias. Additionally, the initially observed effects after 6 weeks were not sustainable in this trial (see Fig. [3](#Fig3){ref-type="fig"}) \[[@CR20]\]. Three studies reached a clinically relevant difference in differences greater than 10% \[[@CR23], [@CR26], [@CR27]\]. Although, Gjelstad et al. observed a statistically significant reduction in prescribing rates, the overall effect of − 1.52% in the IG compared to + 1.7% in the CG is negligible \[[@CR14]\]. Comparing baseline and post-intervention Abx prescription rates, changes within the IGs ranged from + 0.3 to − 23.3% \[[@CR20], [@CR26]\]. Changes within CGs ranged from + 10.1 to − 13.1% \[[@CR20], [@CR29]\].

### Intervention effect of trials with post-intervention measurements {#Sec23}

A total of nine studies reported on post-intervention Abx prescription rates (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR15], [@CR21], [@CR22], [@CR24], [@CR25], [@CR30]--[@CR33]\].

The reported prescription rates ranged from 13.5% \[[@CR21]\] to 67% \[[@CR22]\]. Only four of those trials observed a statistically significant reduction of Abx prescription rates \[[@CR15], [@CR22], [@CR30], [@CR31]\], but only three of them reached a difference between IG and CG exceeding 10% \[[@CR22], [@CR30], [@CR31]\].

All three studies with a factorial design had a positive effect on reducing Abx prescription rates \[[@CR26], [@CR29], [@CR30]\]. Studies with reported prescription rates lower than 20% had no significant reduction in Abx prescribing rates \[[@CR21], [@CR33]\].

Differences of + 2.9% to − 44% were observed in the IGs compared to CGs on post-intervention periods \[[@CR22], [@CR33]\] (see Table [2](#Tab2){ref-type="table"}).

### Effects of single-element interventions {#Sec24}

Single-element interventions address one specific reason for inadequate prescribing. Nine RCTs implemented single-element interventions \[[@CR15], [@CR21], [@CR22], [@CR26], [@CR27], [@CR29], [@CR31]--[@CR33]\], three of them within a factorial study design \[[@CR22], [@CR26], [@CR29]\].

All these RCTs contained interventions addressing either physicians \[[@CR21], [@CR22], [@CR26], [@CR29], [@CR32]\], patients \[[@CR33]\] or diagnosis-making \[[@CR15], [@CR22], [@CR26], [@CR27], [@CR29], [@CR31]\]. In the RCT by Worrall et al., DP with a post-dated prescription did not significantly reduce antibiotic use compared to usual DP \[[@CR32]\]. Hui Min Lee et al. did not find significantly reduced Abx prescriptions by means of patient education on causes of upper RTIs compared to CG (20.6 vs. 17.7% in the CG, OR = 1.20, *p* = 0.313) \[[@CR33]\]. The limited intervention in the RCT by Briel et al. could not significantly reduce Abx prescriptions \[[@CR21]\].

Llor et al. implemented a more effective intervention: After initial consultation, the Abx prescription rate was 44% in the IG (*p* \< 0.001) as compared to 64% in the CG due to RADTs \[[@CR31]\].

McGinn et al. observed an Abx prescription rate of 29% in the IG and a rate of 38% in the CG (*p* = 0.008). Andreeva et al. registered a significant difference in antibiotic prescriptions within 2 weeks after initial consultation: 40.6% in the IG and 71.8% in the CG (*p* = 0.0001) \[[@CR15]\].

In the trial by Cals et al., CRP-POCT reduced the Abx prescription rate by 13% compared to control (*p* \< 0.01) \[[@CR22]\]. Investigating long-term effects, after 3.5 years no effect was found. CST was able to reduce the Abx prescription rate, re-measured 28 days after consultation, by 25% (*p* \< 0.001). After 3.5 years, patients in the CST group received significantly less antibiotic prescriptions for RTIs than in the CG (*p* \< 0.02) \[[@CR34]\].

Little et al. reduced the Abx prescription rate in the cumulative CST group (36 vs. 45%, OR = 0.69; 95% CI 0.54--0.87, *p* \< 0.0001) and CRP POCT group (33 vs. 48%; OR = 0.54; 95% CI 0.42--0.69, *p* \< 0.0001) compared in the control \[[@CR26]\].

Meeker et al. implemented three single-element interventions (two of them focusing at physicians, one focusing at diagnosis-making) in a factorial study design: Intervention 1 "Suggested alternatives" did not significantly reduce Abx prescriptions (*p* = 0.66 for differences in trajectories). Intervention 2 "Accountable Justification" and intervention 3 "Peer comparison" registered significant differences in the rate of inappropriate antibiotic prescribing (*p* \< 0.001) \[[@CR29]\].

### Effects of multifaceted interventions {#Sec25}

Multifaceted interventions address different aspects of inadequate antibiotic prescribing---such as CST or POCT addressing prescribing pressure or diagnostic uncertainty. In most cases, multifaceted interventions contain intervention elements from at least two out of three "target groups": physicians, patients or the process of diagnosis-making \[[@CR13], [@CR20]--[@CR26], [@CR28]--[@CR30]\]. However, according to our definition, a multifaceted intervention can only focus at physicians or patients or diagnosis-making if different aspects are taken into account \[[@CR14]\]: One RCT can just focus at physicians but with prescribing feedback and implementation of DP serving as a multifaceted intervention.

Interventions focusing on patients alone were mostly used as additional elements in multifaceted interventions \[[@CR20], [@CR23], [@CR25], [@CR28]\].

Effects of multifaceted interventions addressing physicians, patients and the process of diagnosis-making {#Sec26}
---------------------------------------------------------------------------------------------------------

Two RCTs implemented interventions addressing all three "target groups". Both trials could significantly reduce their Abx prescription rates \[[@CR23], [@CR28]\]. Gulliford et al. combined a CDSS with patient handouts and DP. The proportion of consultations with antibiotics prescribed declined marginally from 53 to 52% during 12 months after intervention, whereas it remained constant at 52% in the CG. The adjusted mean difference in antibiotic prescriptions was − 1.85% (*p* = 0.038) \[[@CR28]\]. Gonzales et al. observed a reduction of 12% in the first IG (poster with clinical examination algorithm) and a reduction of 13% in the second group (CDSS). Both interventions were combined with patient handouts, feedback on prescribing and seminars for physicians. Compared to CG, both interventions were statistically significant (*p* = 0.003 or *p* = 0.01), but not between themselves (*p* = 0.67) \[[@CR23]\].

Effects of multifaceted interventions addressing physicians and the process of diagnosis-making {#Sec27}
-----------------------------------------------------------------------------------------------

Five RCTs combined physician- and diagnosis-centred interventions \[[@CR13], [@CR22], [@CR24], [@CR26], [@CR30]\], four of them reducing Abx prescription rates to a statistically significant extent \[[@CR13], [@CR22], [@CR26], [@CR30]\]: In their 2010 trial, Cals et al. reduced the Abx prescription rate by 12% (RR in the IG = 0.81, 95% CI 0.62--0.99) within a 28-day follow-up with the help of CRP POCT and DP \[[@CR30]\]. Bjerrum et al. implemented CRP POCT, seminars for physicians and feedback on prescribing. The Abx prescription rate in the IG was 24% (CG 32%) 1 year after the intervention \[[@CR13]\]. In the RCT by Little et al., the combination of CST and CRP-POCT led to a significant reduction of Abx prescriptions compared to CG (58 vs. 32%; *p* \< 0.001) \[[@CR26]\]. As the trial of Cals et al. was designed as a factorial trial, there was no testing for significance for the multifaceted intervention consisting of CRP POCT and CST \[[@CR22]\]. The Abx prescription rate at index consultation was 23% (95% CI 11.6--34.6) and lower than in the CG (67%; 95% CI 53.9--79.5). Prescription rates for follow-up were not indicated. The RCT by Linder et al. from the year 2010 used CDSS and feedback on prescribing and found no difference between IG and CG \[[@CR24]\].

Effects of multifaceted interventions addressing patients and the process of diagnosis-making {#Sec28}
---------------------------------------------------------------------------------------------

The RCT by Linder et al. from 2009 tested patient handouts in combination with a CDSS. This intervention led to a non-significant reduction of 4% in the IG \[[@CR25]\].

Effects of multifaceted interventions addressing patients and physicians {#Sec29}
------------------------------------------------------------------------

In the trial by Altiner et al., the intervention contained patient brochures, a waiting room poster with information on RTI and a CST for physicians. The observed Abx prescription rate after 1 year was 36.7% in the IG compared to 64.8% in the CG. Yet, different baseline rates should be considered (36.4 vs. 54.7%) \[[@CR20]\].

Effects of multifaceted interventions focusing at physicians {#Sec30}
------------------------------------------------------------

Three RCTs used multifaceted interventions focusing at physicians \[[@CR14], [@CR21], [@CR29]\]. Gjelstad et al. observed a reduction of 1.5% in the IG (*p* value = 0.027) \[[@CR14]\]. The IG received feedback on prescribing, DP and seminars for physicians. However, they registered an increase of 1.7% in the CG (*p* value = 0.002). Continuing medical education groups with the corresponding prescription rates served as calculation basis instead of physicians with their individual prescribing rates.

In the trial of Briel et al., physician education alone reduced Abx prescription rates by 5.7%. In combination with CST, the reduction was increased to 7.9% compared to the CG. Both differences were not statistically significant \[[@CR21]\]. The combination of interventions in the RCT by Meeker et al. did not result in statistically significant lowered inappropriate Abx prescription rates compared to CG \[[@CR29]\].

Relevance of intervention effects (see Table [6](#Tab6){ref-type="table"}) {#Sec31}
--------------------------------------------------------------------------

Table [6](#Tab6){ref-type="table"} shows the number of studies and intervention concepts with clinically relevant reductions of Abx prescription rates with regard to type of intervention. Six trials had a meaningful effect on Abx prescription rates \[[@CR22], [@CR23], [@CR26], [@CR27], [@CR30], [@CR31]\]. Three out of these six RCTs had a three-armed or factorial study design, therefore containing more than one intervention concept \[[@CR22], [@CR23], [@CR26]\]. Altogether, our review contains 11 clinically relevant intervention concepts. The majority contained diagnosis-centred elements \[[@CR22], [@CR23], [@CR26], [@CR27], [@CR30], [@CR31]\], especially CRP POCT \[[@CR22], [@CR26], [@CR27], [@CR30]\].

POCT (CRP and RADT) and CST reduce effectively antibiotic prescriptions alone or in combination \[[@CR22], [@CR23], [@CR26], [@CR30]\]. One RCT combined CDSS with knowledge transfer and patient handouts effectively \[[@CR23]\].

### Clinically relevant single-element interventions {#Sec32}

Six single-element intervention concepts could reduce Abx prescription to a clinically relevant extent \[[@CR22], [@CR26], [@CR27], [@CR31]\]. Four out of these six single-element interventions used diagnosis-centred interventions \[[@CR26], [@CR27], [@CR31], [@CR34]\]. All four tested POCT: Three measured the level of CRP \[[@CR22], [@CR26], [@CR27]\], and one RCT used a RADT \[[@CR31]\].

Two RCTs implemented the CST as an intervention focusing at physicians \[[@CR22], [@CR26]\].

### Clinically relevant multifaceted interventions {#Sec33}

Five intervention concepts led to a clinically relevant reduction \[[@CR22], [@CR23], [@CR26], [@CR30]\]. All interventions combined elements focusing at physicians and at the process of diagnosis-making \[[@CR22], [@CR26], [@CR30]\]. Two intervention concepts had additional patient-centred elements \[[@CR23]\]. The diagnosis-centred interventions contained CRP POCT \[[@CR22], [@CR26], [@CR30]\] and CDSS \[[@CR23]\].

Secondary endpoints {#Sec34}
-------------------

Predefined secondary endpoints were patient-centred outcomes (e.g. reconsultation rate \[[@CR21]--[@CR23], [@CR25]--[@CR27], [@CR29]\], patient satisfaction \[[@CR21], [@CR22], [@CR30]\], patients' views on RTIs \[[@CR33]\] or days to recovery \[[@CR22], [@CR26], [@CR27], [@CR30], [@CR31]\]), outcomes related to antibiotic prescribing (e.g. Abx prescriptions according to guidelines \[[@CR24], [@CR25], [@CR31]\], class of prescribed antibiotic \[[@CR13]--[@CR15], [@CR31]\], prescribed antibiotics for specific RTIs \[[@CR13], [@CR28]\]) or diagnostics (e. g. number of X-rays \[[@CR27]\], number of RADTs \[[@CR15]\]). Four RCTs did *not* find any significant difference in secondary endpoints between IG and CG \[[@CR20]--[@CR23]\]. One RCT did not provide any information on secondary endpoints \[[@CR32]\].

### Differences in patient-centred secondary outcomes {#Sec35}

Four trials reported on differences in patient-centred secondary outcomes \[[@CR26], [@CR29], [@CR30], [@CR33]\]. Patient satisfaction was higher in the IG (76.3 vs. 63.2% of patients who were at least very satisfied, *p* = 0.03) \[[@CR30]\]. Patient's understanding of RTI improved (*p* \< 0.001) \[[@CR33]\], and the return visit rate within 30 days after a visit *without* antibiotic prescription was higher in the IG (1.41 vs. 0.43% in the CG, *p* \< 0.001) \[[@CR29]\]. Patients treated by physicians who had been trained in CST required more days for resolution of symptoms in the IG (adjusted risk ratio in the IG 0.83, *p* = 0.002) \[[@CR26]\].

### Differences in physician-centred secondary outcomes {#Sec36}

The Abx prescription rate for patients with specific RTIs such as acute cough and bronchitis was significantly lower in the IG in the trial by Gulliford et al. (− 2.49%, 95% CI 0.15--4.83%, *p* = 0.030) \[[@CR28]\]. Four RCTs reported on prescribed classes of antibiotics \[[@CR13]--[@CR15], [@CR31]\] (see Table [5](#Tab5){ref-type="table"}---intervention influence on prescribed antibiotic class). The trial by Llor et al. is omitted in this table because it did not distinguish between IG and CG \[[@CR31]\]. Two of these four trials witnessed a significant increase of narrow-spectrum penicillins \[[@CR13], [@CR14]\], whereas the proportion of other antibiotic classes declined: In the trial by Gjelstad et al., the prescribing of tetracylines and macrolides decreased significantly in the IG. Simultaneously, the proportion of macrolides increased in the CG \[[@CR14]\]. McGinn et al. observed significant differences only for the prescription rates for quinolones. The prescribing rate in the IG was 9.9% compared to 19.6% in the CG (*p* = 0.02) \[[@CR15]\].Table 5Intervention influence on prescribed antibiotic classAntibiotic prescription ratesStudy arm^a^Narrow-spectrum penicillinsBroad-spectrum penicillinsCephalosporinesMacrolidesQuinolonesTetracyclinesOther classes of antibioticsBjerrum et al. 2006\
Spain\
Included diagnoses: upper/lower RTI (e.g. acute otitis media, tonsillitis, pharyngitis, laryngitis, sinusitis, COPD, pneumonia)IG T00.6% (95% CI 0.0--2.3%)60.7% (95% CI 55.1--66.1%)4.4% (95% CI 2.4--7.3%)17.9% (95% CI 13.9--22.6%)6.3% (95% CI 3.9--9.5%)0.3% (95% CI 0.0--1.7%)9.8% (95% CI 6.7--13.6%)IG T17.9% (95% CI 5.3--11.2%)65.3% (95% CI 60.0--70.3%)0.9% (95% CI 0.2--2.5%)7.0% (95% CI 4.5--10.2%)7.0% (95% CI 4.5--10.2%)0.0% (95% CI 0.0--1.1%)11.9% (95% CI 8.7--15.9%)CG T11.0% (95% CI 0.4--2.0%)70.2% (95% CI 66.7--73.6%)4.7% (95% CI 3.2--6.5%)10.2% (95% CI 8.9--12.6%)6.5% (95% CI 4.9--8.6%)0.1% (95% CI 0.0--0.8%)7.3% (95% CI 5.5--9.5%)Gjelstad et al. 2013\
Norway\
Included diagnoses: acute upper/lower RTI (e.g. bronchitis, tonsillitis, pneumonia, sinusitis)IG T043.8%8.75%n.s.26.6%n.s.19.3%1.23%IG T153.2% (*p* \< 0.001)8.71% (*p* = 0.948)n.s.22.9% (*p* = 0.003)n.s.13.6% (*p* \< 0.001)1.20% (*p* = 0.876)CG T043.5%10.0%n.s.25.5%n.s.19.3%1.43%CG T141.7% (*p* = 0.045)9.78% (*p* = 0.682)n.s.27.8% (*p* = 0.006)n.s.19.2% (*p* = 0.821)1.46% (*p* = 0.908)McGinn et al. 2013\
USA\
Included diagnoses: pharyngitis, pneumoniaPenicillinsCephalosporinesMacrolidesQuinolonesTetracyclinesOther classes of antibioticsIG T124.0%1.2%65.5%9.9%n.s.n.s.CG T122.2% (*p* = 0.75)1.3% (*p* = 0.82)58.8% (*p* = 0.29)19.6% (*p* = 0.02)n.s.n.s.*RTI* respiratory tract infection, *n*.*s*. not specified^a^*IG* intervention group, *CG* control group

Four RCTs categorised the prescribed antibiotics in appropriate or inappropriate prescriptions \[[@CR24], [@CR25], [@CR31]\]. However, definitions for (in-) appropriate prescribing differed: Linder et al. and Meeker et al. defined antibiotic-appropriate (pneumonia, streptococcal pharyngitis, sinusitis, otitis media) and non-antibiotic-appropriate diagnoses (non-streptococcal pharyngitis, influenza, acute bronchitis, non-specific upper RTIs) \[[@CR24], [@CR25]\]. Llor et al. defined antibiotic prescribing for patients *without* group A streptococcal infections as well as missing antibiotic treatment for patients *with* group A streptococcal infections as inappropriate \[[@CR31]\].

Linder et al. implemented a CDSS. When a CDSS was used, the rate of antibiotic prescriptions for diagnoses with appropriate antibiotic treatment was higher as in consultations *without* CDSS (88 vs. 59%, OR = 5.0; 95% CI = 2.9--8.6) \[[@CR25]\]. The rate of non-appropriate antibiotics was lower when physicians used the CDSS (32 vs. 43%, *p* = 0.004) \[[@CR24]\]. Physicians who made use of a CDSS prescribed less antibiotics in all consultations for RTI (42 vs. 50%, *p* = 0.02) \[[@CR24]\]. Meeker et al. found reductions from 15.6 to 19.5% in seven IGs due to behavioural interventions alone or in combination \[[@CR29]\] (see Table [1](#Tab1){ref-type="table"} for details).

In the trial by Llor et al., a RADT test was tested. A higher number of inappropriate antibiotics was observed in the CG (60 vs. 27% in the IG, *p* \< 0.001) \[[@CR31]\].

### Differences in diagnosis-centred secondary outcomes {#Sec37}

The RCT by Andreeva et al. observed a lower rate for chest radiography in the IG (55.4 vs. 76%, *p* = 0.004) \[[@CR27]\].

Discussion {#Sec38}
==========

Summary of main results {#Sec39}
-----------------------

This review updates and summarises current evidence of various interventions in primary care on reducing Abx prescriptions in patients ≥ 13 years for acute RTI. Twelve out of 17 included RCTs showed a statistically significant lower Abx prescription rate in the IG \[[@CR13]--[@CR15], [@CR20], [@CR22], [@CR23], [@CR26]--[@CR31]\]. However, only six of them reported a clinically relevant reduction according to our definition \[[@CR22], [@CR23], [@CR26], [@CR27], [@CR30], [@CR31]\]. Due to the three-armed or factorial study design, these six RCTs contained 11 clinically relevant intervention concepts. Interventions focusing at physicians (CST) and at the process of diagnosis-making (CRP POCT, RADT, CDSS) were---alone or in combination---the most effective interventions. Observed reductions for RCTs with baseline ranged from 1.5 to 23.3% and cannot be compared directly due to heterogeneous baseline Abx prescription rates, study designs and settings \[[@CR14], [@CR26]\]. For studies with post-intervention measurements, the differences between IG and CG were between 2.9 and − 44% \[[@CR22], [@CR33]\]. Studies with reported prescription rates below 20% did not show significant reductions in Abx prescribing rates \[[@CR21], [@CR33]\]. Post-intervention observation periods ranged from 2 weeks up to 3.5 years. Conclusions on long-term sustainability of interventions cannot be drawn.

Meaning of the results and comparison with existing literature {#Sec40}
--------------------------------------------------------------

Our findings are in line with other systematic reviews, which reported mixed results regarding interventions to reduce antibiotics with either a larger or narrower spectrum of interventions and setting \[[@CR7], [@CR8], [@CR10], [@CR38]\]. We focused on RTIs in primary care excluding other infectious conditions and settings like emergency rooms, hospitals or public campaigns \[[@CR39], [@CR40]\].

We included RCTs with single-element \[[@CR15], [@CR22], [@CR26], [@CR27], [@CR29], [@CR31]--[@CR33]\] and multifaceted interventions \[[@CR13], [@CR14], [@CR20]--[@CR26], [@CR29], [@CR30]\] focusing at diagnosis-making \[[@CR13], [@CR15], [@CR22]--[@CR31]\], at physicians \[[@CR13], [@CR14], [@CR20]--[@CR24], [@CR26], [@CR28]--[@CR30], [@CR32]\] or at patients \[[@CR20], [@CR23], [@CR25], [@CR28], [@CR33]\]. Nine intervention concepts with meaningful effects on Abx prescription rates contained interventions addressing the process of diagnosis-making \[[@CR22], [@CR23], [@CR26], [@CR27], [@CR30], [@CR31]\], five of them in combination with interventions targeting physicians \[[@CR22], [@CR23], [@CR26], [@CR30]\]. In contrast to the systematic review of 2005, single-element interventions can be effective (Table [6](#Tab6){ref-type="table"}) \[[@CR22], [@CR23], [@CR26], [@CR27], [@CR30], [@CR31]\]. Interventions addressing patients were less likely to reduce Abx prescriptions to a meaningful extent. POCT (CRP and RADT) and CST---alone or in combination---reduce effectively antibiotic prescriptions \[[@CR22], [@CR23], [@CR26], [@CR27], [@CR30]\].Table 6Clinically relevant interventionsStudyMultifaceted interventionSingle-element interventionIntervention focusing at diagnosis-makingIntervention focusing at physiciansIntervention focusing at patientsDetails about the interventionCals et al. 2009xxxCST + CRP POCTCals et al. 2009xxCSTCals et al. 2009xxCRP POCTCals et al. 2010xxxCRP POCT + DPLlor et al. 2011xRADTGonzales et al. 2013xxxxSoftware for CDSS + knowledge transfer + feedback on prescribing + patient handoutsGonzales et al. 2013xxxxCDSS + knowledge transfer + feedback on prescribing + patient handoutsLittle et al. 2013xxxCST + CRP POCTLittle et al. 2013xxCSTLittle et al. 2013xxCRP POCTAndreeva et al. 2014xxCRP POCT*CDSS* clinical decision support system, *CRP* C-reactive protein, *CST* communication skills training, *DP* delayed prescribing, *POCT* point-of-care test, *RADT* rapid antigen detection test for group A streptococci

Differences in Abx prescription rates and effect sizes {#Sec41}
------------------------------------------------------

We observed large differences in Abx prescription rates between countries ranging from 13.5 and 80% and within a country \[[@CR21], [@CR23]\]. There were five trials from the USA \[[@CR15], [@CR23]--[@CR25], [@CR29]\] where pre-intervention Abx prescription rates ranged from 24 to 80% \[[@CR23], [@CR29]\] and post-intervention Abx prescription rates varied from 29 to 47% \[[@CR15], [@CR24], [@CR25]\]. There were two studies from the Netherlands with post-intervention Abx prescription rates ranging from 23 to 65% \[[@CR22], [@CR30]\]. Two studies from Spain showed post-intervention Abx prescription rates between 24 and 64% \[[@CR13], [@CR31]\]. Pre-intervention Abx prescription rates in the trial of Bjerrum et al. were only available for the IG \[[@CR13]\]. These large variations within and between countries limit the generalisability of the findings and indicate high possibility of selection bias and regional factors affecting Abx prescription rates.

Five included trials did not demonstrate any reduced Abx prescription rates \[[@CR21], [@CR24], [@CR25], [@CR32], [@CR33]\]. Possible reasons for lack of success were possible selection bias in the recruitment of physicians who were already low prescribers \[[@CR21], [@CR33]\], low intervention uptake or insufficient implementation \[[@CR24], [@CR25]\] as well as lack of power due to low number of participating physicians and patients \[[@CR32]\]. We consider five trials reporting statistically significant results as ineffective \[[@CR14], [@CR15], [@CR20], [@CR28], [@CR29]\]. Gulliford et al. used a CDSS in a large sample of family practices and reported a small difference of 1.85% (95% CI − 0.1 to 3.59) \[[@CR28]\]. IG and CG had a similar baseline prescription rate of roughly 50% reflecting overprescribing. The reported statistical significance of the small observed effect is due to the large sample size and cannot be regarded as efficient (difference in differences: − 1%).

Altiner et al. implemented CST, patient brochures and a waiting room poster in the IG \[[@CR20]\]. Despite a large difference in baseline prescription rates and increased Abx prescription rates in the IG (+ 0.3%) and CG (+ 10.1%) within 1 year after baseline, this trial reported statistically relevant reductions after adjusting for seasonal effects and confounding variables such as severity of disease (IG: adjusted OR = 0.72, 95% CI 0.54--0.97, *p* = 0.028; CG: adjusted OR = 1.31, 95% CI 1.01--1.71, *p* = 0.044). This reduction does not satisfy our conditions for a meaningful change (difference in differences − 9.8%).

In the trial of Gjelstad et al., the combination of knowledge transfer, DP and feedback on prescribing resulted in a small difference of − 4.1% between IG and CG \[[@CR14]\]. Due to the large sample size, this trial reported statistically relevant reductions but cannot be regarded as a meaningful change (difference in differences + 0.2%).

Meeker et al. investigated three interventions separately and in combination within a factorial study design \[[@CR29]\]. Although two of the interventions showed a statistically significant and impressive reduction of Abx prescriptions of 17%, this has to be interpreted given that a reduction of 13% in Abx prescriptions was also observed in the CG. An explanation for a reduction without intervention was not given, beside Hawthorne effect. This observation points out the importance of an independent CG and pre- and post-intervention measurements of prescribing rates. Therefore, all trials shown in Fig. [4](#Fig4){ref-type="fig"} lacking pre-intervention measurements have to be interpreted cautiously. For example, McGinn et al. reported a trial with a difference of 9% in Abx prescription rates compared to the CG, just below our arbitrary threshold for minimal significance of 10% \[[@CR15]\]. However, for both groups, no baseline prescription rates are available.

Our review suggests that, in countries with relatively low prescription rates like Germany or the Netherlands, CST seems to be the key element for successful interventions. In contrast, interventions focusing on making a diagnosis in terms of POCT and CDSS showed relevant reductions in high-prescribing countries (e.g. Spain, USA, Russia) \[[@CR13], [@CR23], [@CR27]\]. The role of electronic decision support systems remains unclear.

Secondary outcomes {#Sec42}
------------------

This review also adds to our knowledge that interventions aiming at reducing inappropriate antibiotic prescribing can have a positive effect on the prescribing quality. In a number of trials, the number of narrow-spectrum penicillins increased \[[@CR13], [@CR14]\], whereas the proportion of broad-spectrum antibiotics declined \[[@CR13]--[@CR15]\], although the main focus of the interventions was to *not* prescribe. Effects on patients' satisfaction were reported in three trials \[[@CR21], [@CR22], [@CR30]\]. Only one trial reported a significantly higher proportion of patients satisfied with care in the IG due to CRP-POCT (*p* = 0.03).

Limitations of the review {#Sec43}
-------------------------

Our systematic literature search was limited to few databases and hand search of references due to lack of access to other databases and funding. Additionally, publication bias and the possible exclusion of some foreign language trials have to be acknowledged. Although we cannot exclude that we have missed few trials, we believe this would not have changed our conclusions or allowed summary statistics given the heterogeneity of the designs and outcome measures.

Limitations of trials included {#Sec44}
------------------------------

All included RCTs differed in study design, data collection and time points of measurement, trial quality and baseline prescribing rates. Reporting of trial data was often poor due to missing *p* values, confidence intervals, absolute number of prescriptions and/or baseline data (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Trials with high risk of bias may have led to a too positive interpretation of reported results. The heterogeneity of trial designs and outcome measurements made it impossible to pool trial data or compare effect sizes (e.g. using Cohen's *d*) between trials. Alternatively, we have summarised the baseline and post-intervention Abx prescription rates in Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"} to illustrate the differences and heterogeneity in between trials. There is no consensus about the effect size on Abx prescription rates considered as minimal important change. Our arbitrary assumptions considering an absolute 10% change as minimal important is based on the impression gained from these figures. The majority of trials did not adjust or balance seasonal effects (winter vs. summer), possibly affecting Abx prescription rates.

Conclusions and implications for research {#Sec45}
-----------------------------------------

CST and POCT alone or in combination have the potential to reduce antibiotic prescriptions for RTIs. Electronic decision support tools showed only mixed results. Eleven out of 17 trials were not successful in reducing Abx prescription rates according to our definition of minimal important change \[[@CR13]--[@CR15], [@CR20], [@CR21], [@CR24], [@CR25], [@CR28], [@CR29], [@CR32], [@CR33]\]. However, six of them reported a statistically significant reduction \[[@CR13]--[@CR15], [@CR20], [@CR28], [@CR29]\]. Trials with low initial Abx prescription rates were less likely to be successful. Despite a number of noteworthy current studies, the generated evidence remains disappointingly limited. Only moderate evidence which interventional strategies are successful and how these findings could be generalised beyond the actual setting and the observational period of the trial exist.

We conclude that there is a need to develop a consensus for designing and reporting of trials aiming to reduce inappropriate Abx prescriptions in the near future. It should address (among others) the measurement of pre-intervention prescribing rates, adjustment for seasonal and temporal trends, (minimal) follow-up time, data analysis and reporting.
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